Page 3 - Neil Kumar News Today

- $250 million financing led by Qatar Investment Authority with significant participation from four of the largest investment management firms in the US - BridgeBio anticipates this raise,...

(RTTNews) - BridgeBio Pharma, Inc. (BBIO), a company focused on genetic diseases and cancers, said on Friday that it has inked a deal with certain...

Mizuho Markets Americas LLC lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 5.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 94,198 shares of the company’s stock after purchasing an additional 4,600 shares during the quarter. Mizuho Markets […]

Mizuho restated their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report released on Monday morning, Benzinga reports. The firm currently has a $60.00 target price on the stock. Several other equities analysts have also recently issued reports on BBIO. BTIG Research raised their price target on BridgeBio Pharma from […]

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average […]

BridgeBio Pharma Inc. is free of shareholder litigation over its $175 million buyout of Eidos Therapeutics Inc. after Delaware’s top court rejected self-dealing claims brought by a pension fund.

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price objective lifted by BTIG Research from $32.00 to $42.00 in a research report released on Tuesday morning, FlyOnTheWall reports. Several other research firms have also commented on BBIO. Jefferies Financial Group lowered BridgeBio Pharma from a buy rating to a hold rating and upped their target […]

Jefferies Financial Group cut shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) from a buy rating to a hold rating in a research note published on Monday, Marketbeat reports. They currently have $33.00 price target on the stock, up from their prior price target of $24.00. The analysts noted that the move was a valuation […]

Ronald Daniels and some trustees at the Johns Hopkins University have outside board seats that prompted some critics to raise conflict-of-interest concerns.

BioPharma